TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06489574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural with dexmedetomidine in patients undergoing thoracotomy surgery
Description: A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group A:~Patients will receive 50 μg dexmedetomidine with 10 ml of 0.125% bupivacaine followed by a continuous infusion of (10 ml bupivacaine + 25 μg dexmedetomidine + 39 ml saline with rate of 5 ml per hour).
Study: NCT05742269

Intervention type: DIAGNOSTIC_TEST
Intervention: 89Zr-atezolizumab PET/CT
Description: All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)

Intervention type: DIAGNOSTIC_TEST
Intervention: 89Zr-atezolizumab PET/CT
Description: All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)
Study: NCT04977297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move to Music -Video (M2M-V) Intervention
Description: The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
Study: NCT04794608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYPNO VR® device
Description: The HYPNO VR® device is a software application of medical hypnosis in the treatment of pain and anxiety. It is associated with equipment: a virtual reality headset and a headphone.~Before each session of hypnosis, the nursing staff offers patients the choices: visual universe, musical theme, male or female voice. The nursing staff selects the program, selects a duration of 20 minutes and presses start to start the medical hypnosis session in virtual reality.~After completing the hypnotic trance sequence, as in a classic session, the patient is brought back to the return and exit hypnosis phase under the supervision of the nursing staff.
Study: NCT04973540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iron Bioresorbable Scaffold System (IBS Angel)
Description: Subjects in this arm will be implanted with IBS Angel.
Study: NCT06243367

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
Study: NCT06368895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation delivery through colonoscopy
Description: Patients will receive 4 L of macrogol and salts solution the afternoon before FMT and remain fasting the night before the scheduled treatment. During colonoscopy, about 350 mL of donor fecal preparation will be infused in the cecum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation delivery through oral capsules
Description: Intestinal gastro-resistant capsules (capacity 0.91 mL, overall 10\^8-9 bacteria per capsule) will be filled with the fecal slurry. From each donation weighing 100 g, it is expected to obtain 150 cps, which will be promptly frozen and stored at -80°C. At each monthly visit, the patient will receive 60 capsules, to be stored at -20°C at home. Capsules will be administered orally at the dose of 1 cps twice a day from month 1 post-colonoscopy to patients in the FMT group 1 (colonoscopy plus capsules), and from day 1 to patients in the FMT group 2 (capsules only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation delivery through oral capsules
Description: Intestinal gastro-resistant capsules (capacity 0.91 mL, overall 10\^8-9 bacteria per capsule) will be filled with the fecal slurry. From each donation weighing 100 g, it is expected to obtain 150 cps, which will be promptly frozen and stored at -80°C. At each monthly visit, the patient will receive 60 capsules, to be stored at -20°C at home. Capsules will be administered orally at the dose of 1 cps twice a day from month 1 post-colonoscopy to patients in the FMT group 1 (colonoscopy plus capsules), and from day 1 to patients in the FMT group 2 (capsules only).
Study: NCT05253716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS
Description: Immunonutritional supplement
Study: NCT06428552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Daily rehabilitation program of 40 minutes duration using a mobile application to be completed 6 days per week for 12 weeks
Study: NCT06059430

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05318248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidin
Description: 0,15mg Clonidin orally versus placebo pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study: NCT05622058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Description: TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
Study: NCT06097624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronized tele-exercise
Description: All evaluations and exercise interventions will be performed by via Google Meet, a video-conferencing application. The participation link will be sent to the individual by the researcher before each session. In case of any technological disruption, the session will be postponed to the nearest available time by phone. All interventions will be run by a blinded researcher.
Study: NCT05172440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab combined with axitinib
Description: Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
Study: NCT06094660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic genicular nerve block
Description: Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic genicular nerve block
Description: Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with Radiofrequency Ablation (RFA)
Description: Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with Phenol 6%
Description: Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary.
Study: NCT06470035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active VeNS Device
Description: Battery powered non-invasive neurostimulation device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VeNS Device
Description: Placebo comparator sham device (no active stimulation)
Study: NCT05738967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behavioral therapy (CBT)
Description: Adolescent-caregiver dyads will will participate in CBT focused on exposure therapy and behavioral activation. It will also include flexible incorporation of emotion-focused coping and adaptations for autism.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Adolescent-caregiver dyads will participate in coordinated referrals to the community. They may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
Study: NCT04677751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Description: Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
Study: NCT06036043

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~1. 100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~2. 100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study.
Study: NCT05367271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: 20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
Study: NCT02414178

Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT04910685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet
Study: NCT04369131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
Study: NCT05622318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 25 mg/kg by IV on Days +3 and +4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level \[IV:PO ratio = 1:4\]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
Study: NCT06466590

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of Measurement Instrument
Description: Participants will complete the measurement procedure twice, with sessions scheduled one week apart, using the same instrument under standardized conditions. The results from both sessions will be compared to assess the instrument's consistency and accuracy
Study: NCT05477524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: Shot in the deltoid muscle (preferable in the nondominant arm)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: Shot in the deltoid muscle (preferable in the nondominant arm)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: Shot in the deltoid muscle (preferable in the nondominant arm)
Study: NCT06344494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system
Description: Novel ICE catheter and combined ultrasound system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system
Description: Commercially available devices
Study: NCT05477524

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Shot in the deltoid muscle (preferable in the nondominant arm)
Study: NCT05241405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QISENG
Description: 2 capsules/day for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 2 capsules/day for 8 weeks.
Study: NCT06070857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV232
Description: Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
Study: NCT06522282

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emergency Stroke Unit based on 0.23-T MRI
Description: The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard stroke unit
Description: The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
Study: NCT05462860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprathel®
Description: Application of standard of care dressing.®

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suprathel®
Description: Application of standard of care dressing.®
Study: NCT06246968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab as part of standard of care treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab as part of standard of care treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
Study: NCT06414824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Description: FreeStyle Libre, 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Glucose Monitoring
Description: Standard blood glucose monitoring with glucose meters
Study: NCT06234098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1965 Liposome Injection
Description: AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
Study: NCT05959096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered IV
Study: NCT04740034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 340
Description: AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 340
Description: AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
Study: NCT05322135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FSPG
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Glutamine
Description: Given by vein (IV)
Study: NCT04181047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: Psychotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
Study: NCT05879406

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VitaMedica® Clear Skin Formula capsules
Description: After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)
Study: NCT06246123

Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study: NCT06034938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
Description: Switch previous therapy with DOR/TDF/3TC
Study: NCT05579587

Intervention type: DEVICE
Intervention: Transoral Incisionless Fundoplication
Description: Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
Study: NCT05153499

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CP101
Description: CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05568121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04RD1
Description: 1 tablet of L04RD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04TD1
Description: 1 tablet of L04TD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04TD1
Description: 1 tablet of L04TD1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04RD1
Description: 1 tablet of L04RD1